<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895696</url>
  </required_header>
  <id_info>
    <org_study_id>IM026-024</org_study_id>
    <secondary_id>2019-004021-25</secondary_id>
    <secondary_id>U1111-1241-6528</secondary_id>
    <nct_id>NCT04895696</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness, safety and tolerability of&#xD;
      BMS-986256 in participants with active SLE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">May 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants that achieve an SLE (Systemic Lupus Erythematosus) Responder Index (4) (SRI(4)) response at Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that achieve an SRI(4) response with corticosteroids (CS) reduction and maintenance to ≤ 7.5 mg per day at Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that achieve a British Isles Lupus Assessment Group (BILAG)-based Combine Lupus Assessment (BICLA) at Week 24 and Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve an SRI(4) response without CS reduction and maintenance to ≤ 7.5 mg per day at Week 24</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve a Lupus Low Disease Activity State (LLDAS) response at Week 24 and Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index; Activity (CLASI-A) score ≥ 10 at baseline who achieve a decrease of ≥ 50% from baseline CLASI-A score (CLASI-50) response at Week 24 and Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with 6 or more swollen joints and 6 or more tender joints at baseline who achieve a ≥ 50% reduction from baseline in both swollen and tender joints at Week 24 and Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in swollen joint count using the 28-joint count at Week 24 and Week 48 in participants with ≥ 2 swollen joints at baseline</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in tender joint count at Week 24 and Week 48 using the 28- joint count in participants with ≥ 2 tender joints at baseline</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PGA score of disease activity at Week 24 and Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>PGA = Physician Global Assessment of disease activity (score of &quot;0&quot; indicating no disease activity and higher scores indicating higher disease activity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve CS reduction or maintenance to ≤ 7.5 mg per day at Week 48</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported disease activity from baseline to Week 24 and Week 48 according to the (36-item Short Form Health Questionnaire) SF-36</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>The SF-36 was designed as an indicator of health status in population surveys, and health policy evaluations, and for use as an outcome measure in clinical practice and research. Scores for each domain range from 0 to 100, with high scores indicating a better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience SAEs</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience Adverse Events (AEs)</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience AEs</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in clinical laboratory values: Hematology tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in clinical laboratory values: Hematology tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in clinical laboratory values: Chemistry tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in clinical laboratory values: Chemistry tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in clinical laboratory values: Coagulation tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in clinical laboratory values: Coagulation tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in clinical laboratory values: Urinalysis tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in clinical laboratory values: Urinalysis tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in clinical laboratory values: Serology tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in clinical laboratory values: Serology tests</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in physical examination</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in physical examination</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in vital signs: Body temperature</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in vital signs: Body temperature</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in vital signs: Heart rate</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in vital signs: Heart rate</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in Electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 52 Weeks</time_frame>
    <description>PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in ECG parameters: QRS</measure>
    <time_frame>Up to 52 Weeks</time_frame>
    <description>QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in ECG parameters: QT interval</measure>
    <time_frame>Up to 52 Weeks</time_frame>
    <description>The QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience abnormalities or clinically important changes in ECG parameters: QTcF</measure>
    <time_frame>Up to 52 Weeks</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in ECG parameters: PR interval</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in ECG parameters: QRS</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in ECG parameters: QT interval</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that experience abnormalities or clinically important changes in ECG parameters: QTcF</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>BMS-986256: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986256: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986256: Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986256 (Oral)</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986256: Dose 1</arm_group_label>
    <arm_group_label>BMS-986256: Dose 2</arm_group_label>
    <arm_group_label>BMS-986256: Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Qualify as having Systemic Lupus Erythematosus (SLE), according to the SLE&#xD;
             International Collaborating Clinics (SLICC) Classification Criteria ≥ 12 weeks before&#xD;
             the screening visit&#xD;
&#xD;
          -  Test positive, as determined by the central laboratory, for at least one of the&#xD;
             following lupus related autoantibodies at the time of screening: antinuclear&#xD;
             antibody&gt;/= 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or&#xD;
             anti-Smith antibody.&#xD;
&#xD;
          -  Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score&#xD;
             ≥ 6 points and clinical Hybrid SLEDAI score ≥ 4 points with joint involvement and/or&#xD;
             rash&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active severe lupus nephritis (LN) as assessed by the investigator&#xD;
&#xD;
          -  Neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI&#xD;
&#xD;
          -  Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is&#xD;
             not SLE&#xD;
&#xD;
          -  Antiphospholipid Syndrome&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0042</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1046</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0040</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <state>Tucuman</state>
        <zip>T4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80030110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90610000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>São Bernardo do Campo</city>
        <state>SAO Paulo</state>
        <zip>09715-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>SAO Paulo</state>
        <zip>15092415</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0045</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>São Paulo</city>
        <state>SAO Paulo</state>
        <zip>04032-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Providencia</city>
        <state>Metropolitana</state>
        <zip>7500709</zip>
        <country>Chile</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0043</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cali</city>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0076</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chapinero</city>
        <zip>110221042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zipaquira</city>
        <zip>250252</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0060</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0071</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0061</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986256</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>SLE</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

